Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SynerK Partners with SciWind to Develop siRNA Drugs for Liver and Metabolic Diseases

publication date: Sep 28, 2022

SynerK, a Boston area startup, will partner with Hangzhou’s Sciwind to develop small interfering RNA candidates for liver and metabolic diseases that remain unmet medical needs. The companies will work together to identify new therapeutic targets that play critical roles in disease biology. SynerK has R&D centers in Boston, Suzhou and Beijing. The company, whose founders are RNA industry experts, plans to apply siRNA to treat diseases that have previously been difficult to treat through traditional approaches. SynerK was earlier housed at Massachusetts’ Creagen Life Science Incubato, but is now on its own. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital